Treatment Outcomes and Definition Inconsistencies in High-Risk Unilateral Retinoblastoma: Outcomes and Definition Variances in High-Risk Rb.

High-risk Rb High-risk histopathological features Rb Retinoblastoma

Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
25 Sep 2024
Historique:
received: 24 06 2024
revised: 15 09 2024
accepted: 16 09 2024
medline: 28 9 2024
pubmed: 28 9 2024
entrez: 27 9 2024
Statut: aheadofprint

Résumé

To compare the clinical outcomes of children with unilateral retinoblastoma (Rb) and high-risk histopathology features (HRHF) following upfront enucleation with/without adjuvant chemotherapy, and investigate cases locally considered non-HRHF but converted to a standardized HRHF definition. Retrospective multinational clinical cohort study. Children with Rb who presented to 21 centers from 12 countries between 2011-2020, and underwent primary enucleation were recruited. Centers retrieved clinical data and were asked to report detailed histopathology findings, as well as indicate cases defined locally as high-risk. For analysis, only unilateral cases with standardized HRHF, defined as retrolaminar optic nerve invasion, massive choroidal invasion, scleral invasion, anterior-segment involvement, and/or combined non-massive choroidal and prelaminar/laminar optic nerve invasion, were included. Main Outcome Measures included orbital tumor recurrence, systemic metastasis, survival and number and outcome of cases converted to standardized HRHF. A total of 600 children presenting to 14 centers in 9 countries were included. Of these, 505 (84.2%) were considered locally as HRHF and received adjuvant chemotherapy. After a median follow-up period of 39.2±1.6 months (range: 0.8-60.0 months), 36 (6.0%) had orbital tumor recurrence, 49 (8.2%) metastasis, and 72 (12.0%) children died. Children not receiving adjuvant chemotherapy were at significantly increased risk of orbital tumor recurrence, metastasis, and death (p ≤0.002). Of the study children, 63/600 (10.5%) were considered locally non-HRHF, but converted to standardized HRHF and included in the analysis. Of these, 6/63 (9.5%) had orbital tumor recurrence, 5/63 (7.9%) metastasis, and 6/63 (9.5%) children died. Isolated minor choroidal invasion with prelaminar/laminar optic nerve invasion was reported in 114 (19.0%) children, but considered locally as HRHF only in 68/114 (59.6%). Of these, 6/114 (5.3%) children developed metastasis and subsequently died, yielding a number needed to treat of 15. Based on this multinational cohort of children with Rb, we recommend the use of adjuvant chemotherapy following upfront enucleation and diagnosis of HRHF. Variation exists worldwide among centers when defining HRHF, resulting in adverse patient outcomes, warranting standardization.

Identifiants

pubmed: 39332513
pii: S0002-9394(24)00450-1
doi: 10.1016/j.ajo.2024.09.023
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest None of the authors has any conflicts of interest to disclose.

Auteurs

Mattan Arazi (M)

The Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Alona Baum (A)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Sandro Casavilca-Zambrano (S)

Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520, Surquillo, 15038, Peru.

Sandra Alarcon-Leon (S)

Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520, Surquillo, 15038, Peru.

Rosdali Diaz-Coronado (R)

Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520, Surquillo, 15038, Peru.

Alia Ahmad (A)

University of Child Health Sciences, Children's Hospital Lahore, Ferozepur Road, 54660, Pakistan.

Asma Mushtaq (A)

University of Child Health Sciences, Children's Hospital Lahore, Ferozepur Road, 54660, Pakistan.

Mahvish Hussain (M)

University of Child Health Sciences, Children's Hospital Lahore, Ferozepur Road, 54660, Pakistan.

Tatiana Ushakova (T)

Department of Surgical Methods of Treatment with chemotherapy No. 1 (Head and Neck Tumors), N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation.

Serov Yuri (S)

Department of Surgical Methods of Treatment with chemotherapy No. 1 (Head and Neck Tumors), N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation.

Polyakov Vladimir (P)

Department of Surgical Methods of Treatment with chemotherapy No. 1 (Head and Neck Tumors), N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation.

Carol L Shields (CL)

Wills Eye Hospital, 840 Walnut Street, Philadelphia, Pennsylvania.

Ralph C Eagle (RC)

Wills Eye Hospital, 840 Walnut Street, Philadelphia, Pennsylvania.

Jesse L Berry (JL)

Children's Hospital Los Angeles & USC Roski Eye Institute; Keck School of Medicine.

Sarah Pike (S)

Children's Hospital Los Angeles & USC Roski Eye Institute; Keck School of Medicine.

Brianne Brown (B)

Children's Hospital Los Angeles & USC Roski Eye Institute; Keck School of Medicine.

Soma Rani Roy (SR)

Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh.

Fahmida Huque (F)

Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh.

Ina Fabian (I)

Department of Cell and Developmental Biology, Tel Aviv University, Tel Aviv, Israel.

Shahar Frenkel (S)

Hadassah-Hebrew University Medical Center, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Maya Eiger-Moscovich (M)

Hadassah-Hebrew University Medical Center, Israel.

Jacob Pe'er (J)

Hadassah-Hebrew University Medical Center, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

G Baker Hubbard (GB)

Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA, 30322, USA.

Thomas A Olson (TA)

Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA, 30322, USA.

Hans Grossniklaus (H)

Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA, 30322, USA.

M Ashwin Reddy (MA)

Royal London Hospital, Barts Health NHS Trust, London, England; Moorfields Eye Hospital NHS Foundation Trust, London, England.

Mandeep S Sagoo (MS)

Moorfields Eye Hospital NHS Foundation Trust, London, England.

Sandra E Staffieri (SE)

Department of Ophthalmology Royal Children's Hospital, Parkville, Victoria, Australia, 3052.

James E Elder (JE)

Department of Ophthalmology Royal Children's Hospital, Parkville, Victoria, Australia, 3052.

John D McKenzie (JD)

Department of Ophthalmology Royal Children's Hospital, Parkville, Victoria, Australia, 3052.

Mika Tanabe (M)

Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Swathi Kaliki (S)

The Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India. Electronic address: swathikaliki@lvpei.org.

Ido Didi Fabian (ID)

The Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; London School of Hygiene & Tropical Medicine, London, UK. Electronic address: didi@didifabian.com.

Classifications MeSH